## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.5% in lower entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (0.3%) confirms momentum alignment. Outperforming sector by 2.4%. Caution: momentum weakening (-3.3% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($558.25)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. Ulta Beauty (ULTA): Revisiting Valuation After a Strong Share Price Run**
- Source: Simply Wall Street | 20251217T040854 | Neutral | Relevance: 100%
- Ulta Beauty (ULTA) has seen a strong share price run, outperforming broader retail with an 11% climb over the past month and high 30s year-to-date gains. While its narrative fair value suggests it's 2.3% undervalued at $603, market ratios flash caution with the stock trading at 22 times earnings, higher than the US specialty retail average of 20.3 times. Investors are questioning whether Ulta still offers mispriced growth or if its future potential is already priced in, especially considering risks like persistent wage inflation and the potential loss of its Target partnership.

**2. DRMTLGY Makes Retail Debut Through Exclusive Launch at Ulta Beauty**
- Source: PR Newswire | 20251217T150210 | Bullish | Relevance: 100%
- DRMTLGY, a clinical skincare brand, is launching exclusively at Ulta Beauty in nearly all 1,400+ stores nationwide and on Ulta.com starting December 26. This partnership aims to make high-performance, dermatologist-trusted formulations more accessible to consumers. The lineup will feature 13 of DRMTLGY's most popular products, including serums, creams, cleansers, and SPF.

**3. Zacks Research Boosts Earnings Estimates for Ulta Beauty**
- Source: MarketBeat | 20251217T135053 | Bullish | Relevance: 100%
- Zacks Research has increased its Q4 2026 EPS estimate for Ulta Beauty to $7.68 and provided new forecasts for FY2027 and FY2028 earnings. Several brokers have also raised their price targets, contributing to a "Moderate Buy" consensus rating for ULTA stock. The company recently surpassed quarterly earnings expectations and provided strong FY2025 guidance.

**4. Baird Adjusts Price Target on Ulta Beauty to $700 From $670, Maintains Outperform Rating**
- Source: marketscreener.com | 20251217T113750 | Bullish | Relevance: 100%
- Baird has increased its price target for Ulta Beauty (ULTA) to $700 from $670, while reiterating an Outperform rating on the stock. This adjustment reflects an updated outlook on the company. The article also notes recent adjustments to Ulta Beauty's price targets by other analytical firms.

**5. Drmtlgy Joins Ulta Beautyâ€™s Roster**
- Source: WWD | 20251217T050454 | Bullish | Relevance: 100%
- Ulta Beauty is expanding its dermatological skin care offerings by adding Drmtlgy to its assortment, with a launch planned for December 26 in nearly all 1,400-plus stores and online. The brand will introduce 13 of its top-selling products, ranging from $28 to $69, aiming to make clinically proven results accessible to a broader customer base. Ulta Beauty highlighted the importance of customer sophistication in skincare and Drmtlgy's unique blend of dermatological credibility and modern accessibility as a natural fit.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.52 signals overvaluation risk, limited margin of safety. Forward P/E 21.1x stretched relative to 11% growth. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.6B |
| Beta | 0.87 |
| 52W Range | $309.01 - $611.90 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.52 |
| Forward P/E | 21.1 |
| Current P/E | 23.3 |
| YoY Growth | 10.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 9.8% to 6.5% (-3.3% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 0.3% confirms short-term momentum alignment. AM_20 at 5.6% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.97), confirming momentum. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.45% (CS: 89) | Strong |
| RSI_14 | 63.2 | Neutral |
| MACD Histogram | 1.97 | Bullish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 1.101x | Above |
| vs SMA200 | 1.249x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $594.01
- **Stop Loss:** $558.25 (6.0% risk)
- **Target:** $647.65 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $18,414.31
- **Portfolio %:** 18.41%
- **Risk Dollars:** $1,140.00
- **Risk Per Trade:** 1.14%
- **Modifiers:** L1 95% | L2 120% | Combined 1.14x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.8% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*